Most Clicked StoriesMore >


Pathogen reduction system receives FDA approval

AABB SmartBrief | Dec 17, 2014

Cerus has received FDA approval for its Intercept Blood System. The device uses ultraviolet light and the chemical amotosalen to destroy pathogens in blood plasma, potentially making transfusions safer. The system can be used to decrease infection caused by some viruses and bacteria in plasma collected through apheresis or derived from whole blood, according to the FDA. Reuters (12/16) New York Times (tiered subscription model), The (12/17)


FDA approves pathogen-reduction system for use with platelets

AABB SmartBrief | Dec 19, 2014

Researchers find higher-than-expected risks for surgical transfusions

AABB SmartBrief | Dec 17, 2014

White fat cells can be reprogrammed, study finds

AABB SmartBrief | Dec 15, 2014

Scientists identify genetic switch critical for early stem cell development

AABB SmartBrief | Dec 15, 2014

CDC updates HIV prevention guidelines

AABB SmartBrief | Dec 18, 2014

Study of convalescent serum begins in Liberia

AABB SmartBrief | Dec 16, 2014

Blood test to estimate heart disease risk receives FDA approval

AABB SmartBrief | Dec 16, 2014

Lawmakers urge HHS to change deferral policy on MSM blood donors

AABB SmartBrief | Dec 16, 2014

Trial demonstrates benefits of mechanical removal of clots from brain

AABB SmartBrief | Dec 18, 2014


Find AABB SmartBrief Issues by Date:



AABB News More >


Reminder: Submit Nominations for Memorial Awards

AABB SmartBrief | Dec 19, 2014

AABB to provide feedback to CMS on behalf of facilities that use copper sulfate method to determine hemoglobin

AABB SmartBrief | Dec 18, 2014

Reminder: AABB requests nominations for 2015, 2016 Memorial Awards

AABB SmartBrief | Dec 17, 2014

Early registration discount extended for TransFuse 2015

AABB SmartBrief | Dec 16, 2014

AABB extends deadline to purchase PBM modules at introductory rate

AABB SmartBrief | Dec 15, 2014




Sign up for AABB SmartBrief



Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge. Learn more